Goldman Sachs Group Inc Viracta Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$3.32 - $5.69 $287,747 - $493,157	-86,671 Reduced 42.45%	117,493 $502,000
Q3 2022 Nov 10, 2022	SELL	$3.32 - $5.69 $287,747 - $493,157	-86,671 Reduced 42.45%	117,493 $0
Q2 2022 May 14, 2024	BUY	$1.87 - $5.0 $381,786 - $1.02 Million	204,164 New	204,164 $792,000
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $99,998 - $267,375	53,475 Added 35.49%	204,164 $792,000
Q1 2022 May 16, 2022	SELL	$2.23 - $4.76 $92,683 - $197,835	-41,562 Reduced 21.62%	150,689 $717,000

Q4 2021 Feb 14, 2022	BUY	$3.37 - $7.91 $70,962 - $166,560	21,057 Added 12.3%	192,251 $702,000
Q3 2021 Nov 10, 2021	BUY	$7.84 - $12.53 $1.34 Million - $2.15 Million	171,194 New	171,194 $1.37 Million

9.39M

5.9K

Ticker VIRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,558,200
Market Cap $18.4M
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.